Nalpropion Pharmaceuticals, Inc.
https://www.nalpropion.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nalpropion Pharmaceuticals, Inc.
Lack of Adequate Study Plan Prompts EMA Review Of Cardiovascular Risk With Mysimba
The European Medicines Agency is to recommend whether the marketing authorization for Currax’s weight management drug should be maintained, varied, suspended or revoked.
Novo Nordisk’s Wegovy Gets EU Thumbs Up But Launch Will Wait
Wegovy is set to join Saxenda as the company’s second EU approved drug for obesity, helping it corner the region’s weight-management market, once the company gets its supply back on track.
US FDA Actions On Rx Drug Promos Covered New Territory Last Year
Office of Prescription Drug Promotion issued just six letters citing companies for improper drug promotion in 2020, including the placement of safety information in an email and making unfounded COVID-19 claims. New research projects focus on celebrity endorsements, medical conference materials.
Company Information
- Other Names / Subsidiaries
-
- Currax Pharmaceuticals LLC
- Orexigen Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice